Michael Frumovitz

We now have FOUR potential clinical trials open at @MDAndersonNews for patients with small cell/large cell/neuroendocrine cervical cancer. Both targeted and immunotherapies. Excited to offer so many opportunities to patients with this rare cancer @SARCC @LaurenByersMD

So excited to be at the @Allyson4Rare gala in support of young people with cancer. So appreciative of their amazing support of our #NECC research. @MDAndersonNews @SCCCLCCCSisters

$50K Rhonda’s Award to support research in mucinous ovarian cancer now being offered by the Mucinous Ovarian Cancer Coalition/MOCC. Details/deadlines here: hope4moc.org/researching/ Great opportunity for research in this #raretumor @SGO_org @ESGO_society @IGCSociety @ShelleyMLM

Our trial with immunotherapy AK104 (cadonilimab) for women with neuroendocrine cervix cancer at @MDAndersonNews opened just this week! We already have 1 enrolled and 2 in screening. Trials for #raretumors are possible! @SGO_org @NANETS1 @SCCCLCCCSisters @ShannonWestin @karenluMD

Stay tuned! Our trial with AK104 (cadonilimab), a bispecific PD1/CTLA4 antibody, for women with neuroendocrine cervical cancer should open next week! So close!! @SCCCLCCCSisters @SGO_org @NANETS1